Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Inamrinone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3A known ✓ | Q14432 | 2/20 | 1.00 |
| ▸ | AURKB | Q96GD4 | 12/20 | 1.00 |
| ▸ | INCENP | Q9NQS7 | 12/20 | 1.00 |
| ▸ | TTK | P33981 | 11/20 | 1.00 |
| ▸ | AURKA | O14965 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | CASP1 | P29466 | 2/20 | 1.00 |
| ▸ | PDE3B | Q13370 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | GLA | P06280 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Inamrinone SCHEMBL11447555 | 0.92 | AURKB (0.84) | AURKBINCENPTTKAURKAMAPT | |
| Inamrinone SCHEMBL11467035 | 0.92 | AURKB (0.84) | AURKBINCENPTTKAURKAMAPT | |
| Inamrinone SCHEMBL11449946 | 0.89 | AURKB (0.79) | AURKBINCENPTTKAURKAMAPT | |
| Inamrinone SCHEMBL8627851 | 0.88 | AURKB (0.77) | AURKBINCENPTTKAURKAMAPT | |
| Inamrinone SCHEMBL739746 | 0.85 | AURKB (0.73) | AURKBINCENPTTKAURKAMAPT | |
| Inamrinone SCHEMBL1648759 | 0.84 | AURKB (0.71) | AURKBINCENPTTKAURKAMAPT | |
| SCHEMBL1392973 | 0.81 | AURKB (1.00) | AURKBINCENPTTKAURKAMAPT | |
| SCHEMBL10992408 | 0.81 | AURKB (0.72) | AURKBINCENPTTKAURKAMAPT | |
| SCHEMBL11368332 | 0.80 | TTK (1.00) | AURKBINCENPTTKAURKAMAPT | |
| SCHEMBL10986659 | 0.78 | AURKB (0.64) | AURKBINCENPTTKAURKAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 10273 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605345-B2 | Transdermal drug delivery system | BioPhysics Pharma, Inc. (US) | 2026-04-21 | — | — | US | claimed |
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| EP-4704971-A1 | GAMMA STIMULATION AND NEUROMODULATOR COMBINATION THERAPY | Cognito Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4058037-B1 | FIBROBLAST-BASED THERAPY FOR TREATMENT AND PREVENTION OF STROKE | SPINALCYTE LLC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-2988750-B9 | USE OF LANDIOLOL HYDROCHLORIDE IN THE LONG-TERM TREATMENT OF TACHYARRHYTHMIAS | AOP ORPHAN PHARMACEUTICALS GMBH (AT) | 2025-09-17 | — | — | EP | claimed |
| US-20250268841-A1 | Trans-Epithelial Membrane Drug Delivery System | Masiz, John J. (US) | 2025-08-28 | — | — | US | claimed |
| EP-4594520-A2 | COMPOSITIONS CONTAINING OLIGONUCLEOTIDES WITH THERANOSTIC APPLICATIONS | Sixfold Bioscience Ltd. (GB) | 2025-08-06 | — | — | EP | claimed |
| EP-4561649-A1 | DRUG-COATED MEDICAL DEVICES AND METHODS OF MAKING | Bard Peripheral Vascular, Inc. (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| EP-2988750-B2 | USE OF LANDIOLOL HYDROCHLORIDE IN THE LONG-TERM TREATMENT OF TACHYARRHYTHMIAS | AOP ORPHAN PHARMACEUTICALS GMBH (AT) | 2025-05-28 | — | — | EP | claimed |
| EP-0534706-A1 | Quinazolinones and pyridopyrimidinones useful as angiotensin II antagonists | MERCK & CO. INC. (US) | 1993-03-31 | — | — | EP | claimed |
| WO-1993003711-A1 | DOSAGE FORM FOR DELIVERING DRUG IN SHORT-TIME PERIOD | ALZA CORPORATION (US) | 1993-03-04 | — | — | WO | claimed |
| US-5178867-A | Dosage form for delivering drug in short-time period | ALZA CORPORATION (US) | 1993-01-12 | — | — | US | claimed |
| EP-0490891-A4 | DRUG CONTAINING MATRIX | — | 1992-09-16 | — | — | EP | claimed |
| EP-0490891-A1 | DRUG CONTAINING MATRIX. | UNIV UTAH RES FOUND (US) | 1992-06-24 | — | — | EP | claimed |
| WO-1991003234-A1 | DRUG CONTAINING MATRIX | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 1991-03-21 | — | — | WO | claimed |
| US-4885173-A | ALLOWING PATIENT TO SUCK LOLLIPOP CONTAINING DRUG, WHICH IS RAPIDLY ABSORBED; REMOVING WHEN SYMPTOMS HAVE BEEN RELIEVED | UNIVERSITY OF UTAH (US) | 1989-12-05 | — | — | US | claimed |
| US-4868182-A | HYPOTENSIVE AND CARDIOTONIC, SYNERGISTIC | MERRELL DOW PHARMACEUTICALS INC. (US) | 1989-09-19 | — | — | US | claimed |
| US-4783337-A | Osmotic system comprising plurality of members for dispensing drug | ALZA CORPORATION (US) | 1988-11-08 | — | — | US | claimed |
| US-4072746-A | CARDIOTONIC AGENTS | STERLING DRUG INC. (US) | 1978-02-07 | — | — | US | claimed |